Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae

Cancer Research

Volumn 65, Issue 24, 2005, Pages 11447-11458

  Martin, Sophie ^a,b   Phillips, Darren C ^a   Szekely Szucs, Kinga ^a   Elghazi, Lynda ^a   Desmots, Fabienne ^a   Houghton, Janet A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ALPHA CYCLODEXTRIN; ARACHIDONIC ACID; BETA CYCLODEXTRIN; CERAMIDE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMIPRAMINE; PROCASPASE 8; PROSTAGLANDIN E2; SMALL INTERFERING RNA; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CAVEOLA; CELL MEMBRANE; CELL SURFACE; CELL SURVIVAL; CELLULAR DISTRIBUTION; COLON CARCINOGENESIS; COLON CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIPID METABOLISM; PRIORITY JOURNAL; PROTEIN DOMAIN; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARACHIDONIC ACID; CASPASE 8; CASPASES; CAVEOLAE; CELL MEMBRANE; CERAMIDES; CHOLESTEROL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG RESISTANCE, NEOPLASM; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SPHINGOMYELIN PHOSPHODIESTERASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 29244467982     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1494     Document Type: Article

References (49)

1. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
2. DuBois RN, Tsujii M, Bishop P, et al. Cloning and characterization of a growth factor inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol 1994;266:G822-7.
3. 2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000;19:5517-24.
4. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
5. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
6. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
7. Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-92.
8. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
9. Hallak A, Alon-Baron L, Shamir R, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48:1998-2002.
10. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer 2003;105:868-72.
11. Fenwick SW, Toogood GJ, Lodge JP, Hull MA. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 2003;125:716-29.
12. Tillman DM, Petak I, Houghton JA. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999;5: 425-30.
13. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22: 8628-33.
14. Ozoren N, El-Deiry WS. Defining characteristics of types I and apoptotic cells in response to TRAIL. Neoplasia 2002;4:551-7.
15. Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 2003;63:5118-25.
16. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000;482:193-9.
17. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158:2303-9.
18. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
19. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
20. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
21. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40.
22. Kontny HU, Hammerle K, Klein R, et al. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ 2001;8:506-14.
23. Shin MS, Kim HS, Lee SH, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61:4942-6.
24. van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 2003;89:363-73.
25. Tillman DM, Harwood FG, Gibson AA, Houghton JA. Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells. Cell Death Differ 1998;5:450-7.
26. Zhang D, Li F, Weidner D, Mnjoyan ZH, Fujise K. Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and Fortilin. The potential role of MCL1 as a fortilin chaperone. J Biol Chem 2002;277-37430-8.
27. Persons DA, Allay JA, Allay ER, et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood 1999;93:488-99.
28. Liu B, Hannun YA. Sphingomyelinase assay using radiolabeled substrate. Methods Enzymol 2000;311:164-7.
29. Jayadev S, Hayter HL, Andrieu N, et al. Phospholipase A2 is necessary for tumor necrosis factor á-induced ceramide generation in L929 cells. J Biol Chem 1997;272: 17196-203.
30. Cremesti A, Paris F, Grassme H, et al. Ceramide enables fas to cap and kill. J Biol Chem 2001;276: 23954-61.
31. Grassme H, Schwarz H, Gulbins E. Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem Biophys Res Commun 2001;284:1016-30.
32. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-8.
33. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002;62:4903-8.
34. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005.
35. Totzke G, Schulze-Osthoff K, Janicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 2003;22: 8021-30.
36. Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol 2000;45:389-96.
37. Ricchi P, Di Matola T, Ruggiero G, et al. Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs. Br J Cancer 2002;86:1501-9.
38. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-84.
39. Wu GS, Burns TF, McDonald ER, III, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3.
40. Lacour S, Hammann A, Grazide S, et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004;64: 3593-8.
41. Natoli G, Costanzo A, Guido F, Moretti F, Levrero M. Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem Pharmacol 1998;56:915-20.
42. Delmas D, Rebe C, Lacour S, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 2003;278:41482-90.
43. Brenner B, Ferlinz K, Grassme H, et al. Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases. Cell Death Differ 1998;5:29-37.
44. Veldman RJ, Maestre N, Aduib OM, et al. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem J 2001;355:859-68.
45. Koval M, Pagano RE. Intracellular transport and metabolism of sphingomyelin. Biochim Biophys Acta 1991;1082:113-25.
46. Bilderback TR, Grigsby RJ, Dobrowsky RT. Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae. J Biol Chem 1997;272:10922-7.
47. Liu P, Anderson RG. Compartmentalized production of ceramide at the cell surface. J Biol Chem 1995;270: 27179-85.
48. Grassme H, Cremesti A, Kolesnick R, Gulbins E. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 2003;22:5457-70.
49. Oshima M, Taketo MM. COX selectivity and animal models for colon cancer. Curr Pharm Des 2002;8: 1021-34.